Suppr超能文献

CXCR4 抑制对 FLT3-ITD 阳性人 AML 白血病细胞的影响。

Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts.

机构信息

Department of Pediatrics, University Clinic Carl Gustav Carus Dresden, Dresden, Germany.

出版信息

Exp Hematol. 2010 Mar;38(3):180-90. doi: 10.1016/j.exphem.2009.12.003. Epub 2009 Dec 24.

Abstract

OBJECTIVE

Internal tandem duplication (ITD) mutations of the FLT3 receptor are associated with a high incidence of relapse in acute myeloid leukemia (AML). Expression of the CXCR4 receptor in FLT3-ITD-positive AML is correlated with poor outcome, and inhibition of CXCR4 was shown to sensitize AML blasts toward chemotherapy. The aim of this study was to evaluate the impact of FLT3-ITD on cell proliferation and CXCR4-dependent migration in human hematopoietic progenitor cells and to investigate their response to CXCR4 inhibition.

MATERIALS AND METHODS

We used primary blasts from patients with FLT3-ITD or FLT3 wild-type AML. In addition, human CD34(+) hematopoietic progenitor cells were transduced to >70% with retroviral vectors containing human FLT3-ITD.

RESULTS

We found that FLT3-ITD transgene overexpressing human hematopoietic progenitor cells show strongly reduced migration toward stromal-derived factor-1 in vitro and display significantly reduced bone marrow homing in nonobese diabetic severe combined immunodeficient mice. Cocultivation of FLT3-ITD-positive AML blasts or hematopoietic progenitor cells on bone marrow stromal cells resulted in a strong proliferation advantage and increased early cobblestone area-forming cells compared to FLT3-wild-type AML blasts. Addition of the CXCR4 inhibitor AMD3100 to the coculture significantly reduced both cobblestone area-forming cells and proliferation of FLT3-ITD-positive cells, but did not affect FLT3-wild-type cells-highlighting the critical interaction between CXCR4 and FLT3-ITD.

CONCLUSION

CXCR4 inhibition to decrease cell proliferation and to control the leukemic burden may provide a novel therapeutic strategy in patients with advanced FLT3-ITD-positive AML.

摘要

目的

FLT3 受体内部串联重复(ITD)突变与急性髓系白血病(AML)的高复发率相关。FLT3-ITD 阳性 AML 中 CXCR4 受体的表达与不良预后相关,抑制 CXCR4 可使 AML 白血病细胞对化疗敏感。本研究旨在评估 FLT3-ITD 对人造血祖细胞增殖和 CXCR4 依赖性迁移的影响,并研究它们对 CXCR4 抑制的反应。

材料和方法

我们使用 FLT3-ITD 或 FLT3 野生型 AML 患者的原始白血病细胞。此外,人 CD34+造血祖细胞用含有人 FLT3-ITD 的逆转录病毒载体转导,转导效率>70%。

结果

我们发现,FLT3-ITD 转基因过度表达的人造血祖细胞在体外对基质衍生因子-1的迁移能力明显降低,在非肥胖型糖尿病严重联合免疫缺陷小鼠中骨髓归巢能力显著降低。FLT3-ITD 阳性 AML 白血病细胞或造血祖细胞与骨髓基质细胞共培养可导致明显的增殖优势,并形成更多的早期鹅卵石区形成细胞,与 FLT3 野生型 AML 白血病细胞相比。将 CXCR4 抑制剂 AMD3100 添加到共培养物中可显著降低鹅卵石区形成细胞和 FLT3-ITD 阳性细胞的增殖,但对 FLT3 野生型细胞没有影响,这突出了 CXCR4 与 FLT3-ITD 之间的关键相互作用。

结论

抑制 CXCR4 以减少细胞增殖并控制白血病负荷可能为晚期 FLT3-ITD 阳性 AML 患者提供一种新的治疗策略。

相似文献

1
Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts.
Exp Hematol. 2010 Mar;38(3):180-90. doi: 10.1016/j.exphem.2009.12.003. Epub 2009 Dec 24.
3
FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia.
Oncotarget. 2016 Mar 1;7(9):9964-74. doi: 10.18632/oncotarget.7128.
4
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
Blood. 2009 Jun 11;113(24):6215-24. doi: 10.1182/blood-2008-05-158311. Epub 2008 Oct 27.
7
Flt3 ligand and the Flt3 receptor regulate hematopoietic cell migration by modulating the SDF-1alpha(CXCL12)/CXCR4 axis.
Blood. 2005 Apr 15;105(8):3117-26. doi: 10.1182/blood-2004-04-1440. Epub 2004 Dec 23.

引用本文的文献

1
CXCR4 as a therapeutic target in acute myeloid leukemia.
Leukemia. 2024 Nov;38(11):2303-2317. doi: 10.1038/s41375-024-02326-3. Epub 2024 Sep 11.
2
The interplay of FLT3 and CXCR4 in acute myeloid leukemia: an ongoing debate.
Front Oncol. 2023 Oct 2;13:1258679. doi: 10.3389/fonc.2023.1258679. eCollection 2023.
4
Role of CXCR4 in the progression and therapy of acute leukaemia.
Cell Prolif. 2021 Jul;54(7):e13076. doi: 10.1111/cpr.13076. Epub 2021 May 29.
5
Dysregulation of miR-138-5p/RPS6KA1-AP2M1 Is Associated With Poor Prognosis in AML.
Front Cell Dev Biol. 2021 Feb 26;9:641629. doi: 10.3389/fcell.2021.641629. eCollection 2021.
7
Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.
Biomedicines. 2020 Jul 24;8(8):245. doi: 10.3390/biomedicines8080245.
8
Significance of CXCL12/CXCR4 Ligand/Receptor Axis in Various Aspects of Acute Myeloid Leukemia.
Cancer Manag Res. 2020 Mar 24;12:2155-2165. doi: 10.2147/CMAR.S234883. eCollection 2020.
9
The Current State of FLT3 Inhibition in Acute Myeloid Leukemia - Pitfalls and Promises.
J Cell Signal (Los Angel). 2017;2(4). doi: 10.4172/2576-1471.1000166. Epub 2017 Oct 16.

本文引用的文献

1
Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.
Blood. 2009 Jun 11;113(24):6206-14. doi: 10.1182/blood-2008-06-162123. Epub 2008 Dec 2.
2
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
Blood. 2009 Jun 11;113(24):6215-24. doi: 10.1182/blood-2008-05-158311. Epub 2008 Oct 27.
3
The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation.
Leukemia. 2008 Dec;22(12):2151-5158. doi: 10.1038/leu.2008.238. Epub 2008 Sep 4.
4
Combining SDF-1/CXCR4 antagonism and chemotherapy in relapsed acute myeloid leukemia.
Leukemia. 2009 Feb;23(2):393-6. doi: 10.1038/leu.2008.182. Epub 2008 Jul 10.
5
Abnormal localization and accumulation of FLT3-ITD, a mutant receptor tyrosine kinase involved in leukemogenesis.
Cells Tissues Organs. 2008;188(1-2):225-35. doi: 10.1159/000118788. Epub 2008 Feb 27.
9
Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells.
Leuk Res. 2007 Nov;31(11):1553-63. doi: 10.1016/j.leukres.2007.02.017. Epub 2007 Apr 2.
10
Activation mechanisms of STAT5 by oncogenic Flt3-ITD.
Blood. 2007 Jul 1;110(1):370-4. doi: 10.1182/blood-2006-05-024018. Epub 2007 Mar 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验